For laboratory use only. This product is intended for animal research only and not for use in humans.
This probe specifically targets the anionic phospholipids of bacterial cell membrane, and so targets Gram-negative bacteria slightly more efficiently than Gram-positive bacteria. RediJect Bacterial Detection Fluorescent Imaging Probe is extremely bright, allowing sensitive detection of deep-tissue infections caused by a range of bacteria, including Staphylococcus aureus, Streptococcus pneumoniae, Pseudomonas aeruginosa, Salmonella typhimurium and Escherichia coli.
RediJect Bacterial Detection Fluorescent Imaging Probe Explorer Kit:
| Fluorescent Agent Type | Targeted |
|---|---|
| Optical Imaging Classification | Fluorescence Imaging |
| Product Brand Name | XenoLight |
| Quantity in a Package Amount | 5.0 Units |
| Shipping Condition | Blue Ice |
| Therapeutic Area | Bacterial infection |
| Unit Size | 1 Kit (5 animals) |
| Wave Length | 750 nm |
XenoLight RediJect Bacterial Detection Probe is a Near Infrared,(NIR) fluorescent agent for in vivo targeting of both gram positive and,gram negative bacterial infections. This probe specifically targets the,anionic phospholipids of bacterial cell membrane, and so targets gram,negative bacteria slightly more efficiently than gram positive bacteria.,RediJect bacterial detection probe is extremely bright, allowing sensitive,detection of deep-tissue infections caused by a range of bacteria,including Staphylococcus aureus, Streptococcus pneumoniae,Pseudomonas aeruginosa, Salmonella typhimurium and Escherichia coli.
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.
